Global Journals LaTeX JournalKaleidoscope™
Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. *Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.*

The Cardioprotective Effects of Irbesartan and Candesartan in Isoproterenol Induced Cardiomyopathy in Rats

Jan J. Alshmani[1]

[1] Hawler Medical University

Received: 16 December 2013 Accepted: 5 January 2014 Published: 15 January 2014

Abstract

The presence of a wide selection of angiotensin receptor blockers and the conflicting evidence regarding their cardioprotective effect, led to the attempt to evaluate the impact of irbesartan and candesartan on cardiac hypertrophy and remodeling. Female Albino rats were divided into 3 groups. The first group served as the control group and was given 1 ml distilled water via oral gavage and 0.5 ml distilled water subcutaneously. The second group was the isoproterenol (ISO) group and was given a daily S.C. injection of ISO at a dose of 5 mg/kg. The third group served as the treatment group and it was subdivided into 2 groups, both received ISO as stated previously along with a treatment drug which was administered via oral gavage and they included: ISO-Irb(irbesartan 50 mg/kg/day), and ISO-Cand(candesartan 2.6 mg/kg/day). All groups were treated for a period of 14 days. The assayed parameters included; mean serum Matrix metalloproteinase 9 (MMP-9), Cardiac troponin I (cTn-I), and Heart weight to Body weight (Hw/Bw) ratio.Irbesartan coadministered with ISO significantly reduced mean serum MMP-9 concentration, while candesartan significantly reduced MMP-9, and cTn-I concentrationscompared to the ISO group respectively. The Hw/Bw ratio was significantly reduced by both drugs. In conclusion both treatment drugs possessed some degree of cardioprotection; candesartan being the most beneficial in ameliorating isoproterenol induced cardiac injury.

Index terms— angiotensin, isoproterenol, cardiomyopathy, ARBs, MMP-9, cTn-i, candesartan, irbesartan.

1 Introduction

he human heart is an exceptional organ, that's designed to function continuously for an average 70 year life span of a normal individual, thus a human heart beating at a rate of 70 beats per minute will exceed 2.5 billion beats throughout the life span of a human being (McCartan et al., 2012), this exceptional muscular pump displays extraordinary capacity to adapt to a broad range of genetic and extrinsic factors to sustain its contractile functions, failure to do so results in cardiac dysfunction and cardiomyopathy (Harvey and Leinwand, 2011). Cardiomyopathies are defined as "a heterogeneous group of diseases involving the myocardium which are associated with mechanical and/or electrical dysfunction that usually exhibits inappropriate ventricular hypertrophy or dilation and are due to a variety of causes that frequently are genetic" Author ?: Hawler Medical University. e-mail: jjann1979@hotmail.com (Maron et al., 2006). They can be classified either into primary, or secondary; or according to the type of cardiomyopathy into dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC) (Wexler et al., 2009) DCM is a progressive, irreversible condition with an estimated prevalence of 1:2500, and is considered one of the leading causes of heart failure (Burke, 2011). HCM is regarded as a leading cause of death among athletes, and has an incidence of 1:500 (Maron, et al., 2006), while RCM and ARVC are considered rare types of cardiomyopathy (Wexler et al., 2009). Many biomarkers have been associated

with cardiac remodeling and cardiomyopathy (Gopal and Sam, 2013), among these is the cTn-I and MMP-9, their elevation is involved in cardiac injury and cardiomyopathy (Herman et al., 1999;Fairweather et al., 2011), in addition the renin angiotensin system (RAS) can induce left ventricular hypertrophy and fibrosis (Ocaranza et al., 2002), due to the direct effect of Ang II on myocardial cell hypertrophy through its action on the AT 1 receptor (Mehta and Griendling, 2007).

2 II.

3 Materials and Methods

Thirty six female albino rats, 8-12 weeks old, weighing 140-200 grams, were used. The animals were housed in groups of four per cage, on sawdust in the animal house facility, under conditions of controlled ambient temperature of 22-25 oC with a 12 hour light/ dark cycles. The animals were supplied with rodent chow and free access to tap water.

a) The Rats were allocated into 3 groups as follow Group 1: (Control group) This group included 8 rats and served as the control group; they received 1ml distilled water orally via oral gavage and 0.5 ml distilled water subcutaneously for a period of 14 days. Group 2: (ISO group) included 8 rats and served as a model of isoproterenol induced cardiomyopathy. The animals were injected with isoproterenol hydrochloride in a dose of 5mg/kg/day (Tipnis et al., 2000;Heather et al., 2009;Chowdhury et al., 2013), S.C. for a period of 14 days to induce distinguishable cardiac hypertrophy and cardiomyopathy. Group 3: (Treatment group) included 20 rats, and served as the treatment group; they were T b) Serum Measurements Rat Matrix Metalloproteinase 9 and Cardiac troponin I serum concentrations were measured bydouble-antibody sandwich enzyme-linked immuneosorbent assay (ELISA), purchased from Uscn life science/ Germany and QAYEE-BIO/ Germany respectively.The Hw/Bw ratio was calculated by dividing the heart weight (mg) over the body weight (gm.). **??**Suckowet al, 2005).????\???? ð ??”ð ??”ð ??”ð ??”ð ??”ð ??”ð ??”ð ??”ð ??”ð ??” = ?????????? ???????????? ???? ???? ??ð ??”ð ??”???? ????ð ??”ð ??”????ð ??”ð ??” ð ??”ð ??”?? ???? c) Statistical Analysis

All data are expressed as Mean ± standard deviation. Data was analyzed using the Statistical Package for Social Sciences (SPSS) version 16. Data analysis was made using one-way analysis of variance (ANOVA). Comparison between groups was done by using Post Hoc LSD test. P?0.05 was considered statistically significant.

4 III.

5 Results

By the end of the study the following mortality was recorded: 2 of 10 rats in the ISO-Cand group. These animals were excluded from the study.

The table below shows the effect of coadministration of the treatment drugs with isoproterenol on the studied parameters. Irbesartan in its respective group, significantly reduced mean serum MMP-9 concentration to 8.10±2.32 ng/ml, while candesartan significantly reduced both serum concentrations of MMP-9 (8.25±1.96 ng/ml) andcTn-I (67.47±10.06 ng/ml,). The Hw/Bw ratio was significantly reduced by both treatment drugs. The Cardioprotective Effects of Irbesartan and Candesartan in Isoproterenol Induced Cardiomyopathy in Rats further subdivided into 2 subgroups all of which received isoproterenol as stated previously for group 2, along with the treatment drug administered via oral gavage, and they include: Group 3.1 (ISO-Irb. group): This group included 10 rats that were given irbesartan 50mg/kg/day. Group 3.2(ISO-Cand. group): This group included 10 rats that were given candesartan 2.6 mg/kg/day. All groups were treated for a period of 14 consecutive days. Isoproterenol hydrochloride solution was prepared by reconstitution of isoproterenol hydrochloride powder with distilled water daily under sterile conditions immediately before injection (Grimm et al., 1998). The rats were first weighed and then isoproterenol was injected S.C into each rat except control group which was injected with distilled water S.C. The subcutaneous route was used because of the higher levels of cTn-I associated with this route, and a greater degree of cardiac injury (Brady et al., 2010). Immediately after the injection, the rats received the corresponding treatment drug according to the stated dose for each group, (except for the control group and the ISO group). After 14 days, 24hr of the last dose, the rats were anesthetized by injecting thiopental sodium 100mg/kg/I.P (Grimm et al., 1998), then dissected to expose the beating heart, after which blood was withdrawn directly from the right ventricle. The withdrawn blood was placed in a graduated glass conical bottom centrifuge tubes and allowed to settle for 20 min after which it was centrifuged at 3000 RPM for 10 minutes. The obtained serum was placed in eppendorf tubes and stored at -20 oC for further analysis; the heart was extracted, dried with filter paper and weighed.

Figure 1: -



1

Figure 2: Figure 1 :

1

Groups		MMP-9 ng/ml		cTn-I ng/ml		Hw/Bw ratio
Control		7.66±1.50		70.35±13.27		3.15±0.35 4.53±0.31
ISO	ISO-Irb	11.38±3.41	*	85.58±10.95	*	* 3.76±0.29 a
		8.10±2.32 a		80.42±14.07		
ISO-Cand		8.25±1.96 a		67.47±10.06 ab		3.65±0.20 a
P-Value		0.015		0.019		<0.001

Figure 3: Table 1 :

[Chowdhury et al. ()] 'A proteomic view of isoproterenol induced cardiac hypertrophy: Prohibitin identified as a potential biomarker in rats'. D Chowdhury , A D Tangutur , T N Khatua , P Saxena , S K Banerjee , M P Bhadra . *J. Transl Med* 2013. Issue1. 11 p. .

[Mehta and Griendling ()] 'Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system'. P K Mehta , K K Griendling . *Am J Physiol Cell Physiol* 2007. 292 (1) p. .

[Gray et al. ()] 'Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endotheline-1 from fibroblasts'. M O Gray , C S Long , J E Kalinyak , H T Li , J S Karliner . *Cardiovasc Res* 1998. 40 (2) p. .

[Burnier ()] 'Angiotensin II Type 1 Receptor Blockers'. M Burnier . *Circulation* 2001. 103 (6) p. .

[Ichihara et al. ()] 'Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension'. S Ichihara , T Senbonmatsu , E PriceJr , T Ichiki , F A Gaffney , T Inagami . *Circulation* 2001. 104 (3) p. .

[Tipnis et al. ()] 'Attenuation of isoproterenol-mediated myocardial injury in rat by an inhibitor of polyamine synthesis'. U R Tipnis , G Y He , S Li , G Campbell , P J Boor . *CardiovascPathol* 2000. 9 (5) p. .

[Fairweather et al. (ed.) ()] *Biomarkers of Heart Failure in Myocarditis and Dilated Cardiomyopathy*, D Fairweather , E D Abston , M J Coronado . D. Cihakova (ed.) 2011. Croatia, P: InTech Europe Pub. 16 p. .

[Brady et al. ()] 'Cardiac troponin I in isoproterenol-induced cardiac injury in the Hanover Wistar rat: studies on low dose levels and routes of administration'. S Brady , M York , C Scudamore , T Williams , W Griffiths , J Turton . *ToxicolPathol* 2010. 38 (2) p. .

[Mccartan et al. ()] 'Cardiomyopathy Classification: Ongoing Debate in the Genomics Era'. C Mccartan , R Mason , S R Jayasinghe , L R Griffiths . ID-796926. *Biochem Res Int* 2012. 2012.

[Wexler et al. ()] 'Cardiomyopathy: An Overview'. R Wexler , T Elton , A Pleister , D Feldman . *Am Fam Physician* 2009. 79 (9) p. .

[Harvey and Leinwand ()] 'Cellular mechanisms of cardiomyopathy'. P A Harvey , L A Leinwand . *JCB* 2011. 194 (3) p. .

[York et al. ()] 'Characterization of troponin responses in isoproterenol-induced cardiac injury in hanoverwister rats'. M York , C Scudamore , S Brady , C Chen , S Wilson , M Curtis , G Evans , W Griffiths , M Whayman , T Williams , TurtonJ . *Toxi. Path* 2007. 35 (4) p. .

[Palaniyappan et al. ()] 'Comparison of Vasopeptidase inhibitor Omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction'. A Palaniyappan , R R E Uwiera , H Idikio , B I Jugdutt . *Mol Cell Biochem* 2009. 321 (1-2) p. .

[Verdecchia et al. ()] *Comparitive assessment of angiotensin receptor blockers in different clinical settings, Vasc Health Risk Manag*, P Verdecchia , F Angeli , S Repaci , G Mazzotta , G Gentile , ReboldiG . 2009. 2009. p. .

[Maron et al. ()] 'Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention'. B J Maron , J A Towbin , G Thiene , C Antzelevitch , D Corrado , D Arnett , A J Moss , C E Seidman , YoungJ B . *Circulation* 2006. 113 (14) p. .

[Herman et al. ()] 'Correlation between serum levels of cardiac Troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin'. E H Herman , J Zhang , S E Lipshultz , N Rifai , D Chadwick , K Takeda , Z X Yu , V J Ferrans . *J. ClinOncol* 1999. 17 (7) p. .

[Grimm et al. ()] 'Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system'. D Grimm , D Elsner , H Schunkert , M Pfeifer , D Griese , G Bruckschlegel , F Muders , G A J Riegger , E P Kromer . *Cardiovasc Res* 1998. 37 (1) p. .

[Burke ()] 'Dilated Cardiomyopathy Pathology'. A P Burke . *Medscape: Drugs, Diseases and Procedures*, A P Burke (ed.) 2011.

[Montalescot et al. ()] 'Effect of Irbesartan and Enalapril in non-ST elevation acute coronary Syndrome: Results of the double-blind ARCHIPELAGO study'. G Montalescot , H Drexler , R Gallo , T Pearson , M Thoenes , D L Bhatt . *Euro. Heart J* 2009. 30 (2) p. .

[Shirai et al. ()] 'Effects of angiotensin-II receptor blocker candesartan cilexetil in rats with dilated cardiomyopathy'. K Shirai , K Watanabe , M Ma , M I Wahed , M Inoue , Y Saito , P S Suresh , T Kashimura , H Tachikawa , M Kodama , Y Aizawa . *Mol Cell Biochem* 2005. 269 (1-2) p. .

[Richer et al. ()] 'Effects of longterm angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats'. C Richer , P Fornes , C Cazaubon , V Domergue , D Nisato , J F Giudicelli . *Cardiovasc Res* 1999. 41 (1) p. .

[Ocaranza et al. ()] 'Isoproterenol and Angiotensin I-Converting Enzyme in Lung, Left Ventricle, and Plasma During Myocardial Hypertrophy and Fibrosis'. M P Ocaranza , G Diaz-Araya , M Chiong , D Mu?oz , J P Riveros , R Ebensperger , S Sabat , P Irarr?zaval , J E Jalil , S Lavandero . *J. Cardio. Pharma* 2002. 40 (2) p. .

[Cheng et al. ()] 'Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKC? in the heart, which are mitigated by endothelin receptor antagonist CPU0213'. Y S Cheng , D Z Dai , Y Dai . *ActaPharmcol. Sin* 2009. 30 (8) p. .

[Heather et al. ()] 'Isoproterenol induces in vivo functional and metabolic abnormalities; similar to those found in the infarcted rat heart'. L C Heather , A F Catchpole , D J Stuckey , M A Cole , C A Carr , K Clarke . *J PhysiolPharma* 2009. 60 (3) p. .

[Boluyt et al. ()] 'Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart'. M O Boluyt , X Long , T Eschenhagen , U Mende , W Schmitz , M T Crow , E G Lakatta . *Am J. Physiol* 1995. 269 (2) p. . (Pt 2)

[Roldán et al. ()] 'Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy'. V Roldán , F Marín , J R Gimeno , F Ruiz-Espejo , J González , E Feliu , A García-Honrubia , D Saura , G Morena , M Valdés , V Vicente . *Am Heart J* 2008. 156 (1) p. .

[Li et al. ()] 'Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure'. L Li , Y Zhang , Y Li , B Yu , Y Xu , S Zhao , GuanZ . *Transpl. Int* 2008. 21 (12) p. .

[Kim and Iwao ()] 'molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases'. S Kim , H Iwao . *Pharmacol Rev* 2000. 52 (1) p. .

[Gopald ()] 'New and emerging biomarkers in left ventricular systolic dysfunction–insight into dilated cardiomyopathy'. Sam M F Gopald . *J. of Cardiovasc. Trans. Res* 2013. 6 p. .

[Deschamp and Spinale ()] 'Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation'. A M Deschamp , F G Spinale . *Cardiovasc Res* 2006. 69 (3) p. .

[Serra et al. ()] A J Serra , M L Higuchi , S S M Ihara , E L Antônio , M H H Santos , M T N M Bombig , P J F Tucci . *Exercise training prevents ?-adrenergic Hyperactivity-induced Myocardial Hypertrophy and Lesions*, 2008. 10 p. .

[Kakuta and Sudoh ()] 'Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers'. H Kakuta , K Sudoh , M , YamagishiS . *Int J Clin Pharmacol Res* 2005. 25 (1) p. .

[Babuin and Jaffe ()] 'Troponin: the Biomarker of choice for the detection of Cardiac Injury'. L Babuin , A S Jaffe . *CMAJ* 2005. 173 (10) p. .